HC Wainwright Has Lowered Expectations for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price

Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target lowered by research analysts at HC Wainwright from $14.00 to $11.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 450.00% from the stock’s current price.

RVPH has been the topic of a number of other reports. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, January 10th. D. Boral Capital restated a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday. Roth Mkm assumed coverage on Reviva Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $7.00 price target for the company. Finally, Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Reviva Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $11.40.

Reviva Pharmaceuticals Trading Up 13.0 %

Shares of NASDAQ RVPH opened at $2.00 on Wednesday. The stock has a market cap of $66.88 million, a price-to-earnings ratio of -1.80 and a beta of -0.12. The company’s 50-day moving average price is $1.67 and its 200 day moving average price is $1.32. Reviva Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $4.83.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A hedge fund recently bought a new stake in Reviva Pharmaceuticals stock. Drive Wealth Management LLC purchased a new stake in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 20,000 shares of the company’s stock, valued at approximately $36,000. Drive Wealth Management LLC owned approximately 0.06% of Reviva Pharmaceuticals as of its most recent SEC filing. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.